CT-based AI to predict outcomes after kidney cancer surgery
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment (AI-Kidney-Prognosis)
This project will try CT-based AI models to predict post-surgery outcomes for adults treated for kidney cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT07118813 on ClinicalTrials.gov |
What this trial studies
This prospective observational cohort at Union Hospital (Wuhan) will collect pre-treatment abdominal CT scans and clinical data from adult patients who had surgery for renal cell carcinoma between August 2025 and August 2026. Radiomics features will be extracted from those CT images and used to train and validate machine-learning models to predict clinical outcomes after surgery such as recurrence or progression. The study does not alter clinical treatment and will follow patients over time to compare predicted risk with actual outcomes. Results are intended to inform personalized follow-up strategies and support clinical decision-making using noninvasive imaging.
Who should consider this trial
Good fit: Adults (over 18) who underwent surgery for renal cell carcinoma at Wuhan Union Hospital between August 2025 and August 2026, have a pre-treatment abdominal CT scan, and a pathology-confirmed RCC diagnosis.
Not a fit: Patients with poor-quality or missing CT images, incomplete clinical data, loss to follow-up, another primary cancer, or unclear pathology are unlikely to benefit from the model.
Why it matters
Potential benefit: If successful, the models could help doctors personalize follow-up and treatment decisions by identifying patients at higher risk of recurrence after surgery.
How similar studies have performed: Retrospective radiomics and AI studies in renal cell carcinoma have shown promising predictive performance, but prospective validation like this study remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026; 2. Aged \> 18 years old; 3. At least one abdominal CT scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma. Exclusion Criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than renal cell carcinoma; 4. Unclear pathological diagnosis.
Where this trial is running
Wuhan, Hubei
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Lian Yang
- Email: yanglian@hust.edu.cn
- Phone: 18986273791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.